Introduction to Maternal Tdap and Infant Immunity

Protecting vulnerable infants from life-threatening infections begins long before their first pediatric visit. Maternal immunization with the Tdap vaccine has become a cornerstone of prenatal care, aimed at transferring protective antibodies across the placenta. This strategy specifically targets the immunity gap during the first few months of life when infants are too young for their own vaccinations. Recent clinical research has focused on how these maternal antibodies interact with subsequent infant vaccination series. One primary concern for clinicians is whether maternal Tdap vaccination impacts the long-term hexavalent vaccine antibody persistence in children. Hexavalent vaccines, which combine protection against diphtheria, tetanus, acellular pertussis, inactivated poliovirus, hepatitis B, and Haemophilus influenzae type b, are increasingly used in India. Understanding the durability of the immune response through the toddler years and into school age is essential for optimizing public health policy. This study provides vital evidence that both term and preterm infants maintain significant protection, reinforcing the importance of current maternal and childhood vaccination schedules.

Long-Term Durability of the Immune Response

The persistence of circulating antibodies is a key indicator of a vaccine's long-term effectiveness. Researchers followed cohorts of children from infancy through age five to assess how antibody levels for six critical antigens changed over time. The data revealed that antibody concentrations naturally declined between the ages of three and five years across both term and preterm groups. This decline was expected as the immediate effect of the toddler booster wore off. However, the study highlighted that seroprotection rates remained remarkably high for most antigens. Diphtheria and tetanus toxoids, as well as poliovirus antibodies, showed excellent durability during this period. Interestingly, antibodies against Hepatitis B exhibited a more pronounced decline compared to other components. Despite this specific trend, the overall immune profile suggests that the initial series provides a robust foundation for childhood immunity. For practitioners in India, where infectious disease burdens remain significant, these findings offer reassurance that the hexavalent platform provides reliable, lasting protection against multiple pathogens simultaneously.

Hexavalent Vaccine Antibody Persistence in Preterm Infants

Preterm infants often face unique challenges regarding their immune system development and response to vaccines. Historically, there have been concerns that their immature systems might not sustain antibody levels as effectively as term infants. The study addressed this by specifically comparing antibody persistence in children born prematurely versus those born at full term. While antibody levels were generally higher in term children, the preterm group demonstrated comparable seroprotection rates for most antigens at ages three and five. This is a critical finding because it validates the use of standard hexavalent schedules in the preterm population. Furthermore, the presence of maternal Tdap antibodies did not negatively impact the long-term hexavalent vaccine antibody persistence in these children. This data is particularly relevant for neonatologists and pediatricians who manage the care of preterm babies, as it confirms that these infants can achieve and maintain protective levels of immunity. Consequently, clinicians can confidently recommend the standard vaccination timeline, ensuring that even the most fragile patients receive full protection against preventable diseases.

Immunogenicity of School-Age Booster Vaccinations

As children reach school age, their risk of exposure to various pathogens increases due to closer contact with peers. Therefore, a school-age booster is often recommended to reinforce waning immunity. This study evaluated the immunogenicity of an acellular pertussis-containing booster administered between five and seven years of age. One month following this booster dose, antibody levels increased markedly for every antigen assessed. The results were highly impressive, with seroprotection rates reaching 100% in both term and preterm groups for diphtheria, tetanus, and poliovirus type 1. Additionally, protection against poliovirus types 2 and 3 remained above 96%. Pertussis response rates were also excellent, with over 93% of children showing significant seroconversion. These findings suggest that the primary and toddler series effectively prime the immune system for a strong anamnestic response later in childhood. This reinforces the necessity of the school-age booster to maintain community-level protection and prevent outbreaks of pertussis and other diseases in educational settings.

Implications for Maternal Vaccination Strategies

The success of infant vaccination programs is deeply intertwined with maternal health policies. This research strongly supports the current strategy of vaccinating pregnant women with Tdap. By demonstrating that maternal antibodies do not interfere with the long-term immune memory or the response to later boosters, the study removes a significant theoretical barrier to prenatal immunization. In India, where the Indian Academy of Pediatrics advocates for maternal Tdap, this evidence is invaluable for addressing vaccine hesitancy among expecting parents. Moreover, the study highlights that the fully liquid hexavalent vaccine is both immunogenic and convenient, potentially improving compliance rates. The consistency of results across both term and preterm infants suggests that maternal vaccination provides a universal benefit without compromising the infant's future vaccine efficacy. As public health initiatives strive for higher coverage, these data provide a clear clinical pathway for protecting the next generation from birth through their early school years.

Clinical Relevance in the Indian Healthcare Context

Integrating global research findings into the Indian clinical landscape requires a nuanced understanding of local guidelines and disease prevalence. India has transitioned many of its immunization efforts toward hexavalent and pentavalent combinations to simplify schedules and reduce the number of injections. The evidence regarding hexavalent vaccine antibody persistence aligns perfectly with the goals of India’s Universal Immunization Programme and the recommendations of private pediatric bodies. Because pertussis remains endemic in many parts of the country, ensuring high antibody titers through maternal and booster doses is a public health priority. Furthermore, the findings regarding Hepatitis B persistence are particularly noteworthy for Indian doctors, as the country continues to work toward eliminating viral hepatitis. This study encourages clinicians to stay vigilant about booster schedules and to continue advocating for maternal Tdap as a safe and effective method to protect newborns. By adhering to evidence-based protocols, healthcare providers can ensure that the gains made in childhood survival are sustained throughout adolescence.

Frequently Asked Questions

How does maternal Tdap vaccination affect the infant's long-term immune response?

Maternal Tdap vaccination provides essential early protection by transferring antibodies to the fetus. Research indicates that these maternal antibodies do not hinder the infant's ability to develop long-term immunity following their own primary vaccination series. Although some studies show a slight temporary blunting of certain antibody levels, the overall persistence of protection and the ability to respond to future boosters remain robust and clinically effective for both term and preterm children.

Is the hexavalent vaccine equally effective for children born prematurely?

Yes, the hexavalent vaccine is highly effective for preterm infants. While preterm children may initially have slightly lower antibody concentrations compared to those born at full term, they achieve comparable and high seroprotection rates for most antigens. Long-term studies show that by ages three and five, preterm children maintain protective levels of antibodies against diphtheria, tetanus, and polio, and they respond vigorously to school-age booster doses later in childhood.

Why is a school-age booster vaccine necessary if primary vaccination was successful?

Even after successful primary and toddler vaccinations, antibody levels for certain diseases like pertussis and hepatitis B can decline over several years. A school-age booster is critical because it triggers an anamnestic response, rapidly increasing antibody titers to protective levels. This ensures that children entering school environments, where exposure risks are higher, remain fully protected against infection and helps maintain herd immunity within the community to prevent outbreaks.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

De Weerdt L et al. Antibody persistence following primary and toddler booster vaccination of a hexavalent DTaP-IPV-HB-PRP∼T vaccine and immunogenicity of a school-age aP-containing booster vaccine in term and preterm infants born to women vaccinated with Tdap during pregnancy. Vaccine. 2026 Jul 10. doi: undefined. PMID: 42430876.

Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP). Revised IAP Immunization Schedule 2024-25. Indian Pediatrics. 2024.

Maternal Tdap vaccination and infant immune response: A systematic review and meta-analysis. Vaccine Integrity Project, University of Minnesota. 2026.